Human Genomics · Aug 15, 2026

Evaluation of a polygenic risk score for breast cancer in Chinese women: a three-stage case-control study of 13,715 subjects

By Lin Y, Zou S, Yang G et al.

INTRODUCTION: Polygenic risk score (PRS) is a valuable tool for predicting the risk of breast cancer (BC). However, limited studies have been conducted in Chinese women. This study aimed to develop and validate a PRS which could be used to identify individuals with high risk of breast cancer. The associations between the PRS and patients' clinicopathological characteristics or survival outcomes were also evaluated. METHODS: We developed a PRS based on genome-wide association studies (GWAS)-identified risk variants with a three-stage design across four cohorts. In total, 7,056 patients and 6,659 controls were enrolled from Fujian Medical University Union Hospital (FJMUUH) and Shanghai Breast Cancer Genetics Study (SBCGS). Five approaches were utilized to calculate the PRS, including repeated logistic regression (RLR), logistic ridge regression (LRR), artificial neural network (ANN), random forest (RF) and support vector machine (SVM). Logistic regression analyses were performed to assess the association between established PRS and clinicopathological characteristics. The correlation between PRS and patients' survival outcomes was evaluated by Cox regression models. RESULTS: Overall, 7 SNPs were selected for PRS development. PRSLRR achieved robust and stable performance across cohorts, yielding an area under the receiver operating characteristic curve (AUC) of 0.633 and an OR of 1.64 per 1 SD increase. Women in the top5% and 80-95% percentiles of PRS had a 4.32-fold and a 1.40-fold elevated risk of developing breast cancer compared with those at average risk (PRS in 40-60th percentiles). The predictive performance of PRS for patients with human epidermal growth factor receptor-2 (HER-2) positive tumors was demonstrated to be higher than that of HER-2 negative tumors (AUC = 0.671 vs. 0.623). It was also identified that the PRS was not correlated with age at diagnosis or tumor characteristics. In multivariable Cox models, high PRS was associated with worse overall survival (OS) in the overall cohort (adjusted HR = 1.39, 95%CI = 1.08-1.78, p = 0.010) and unfavorable disease-free survival (DFS) (adjusted HR = 1.41, 95%CI = 1.03-1.95; p = 0.035)/OS (adjusted HR = 1.64, 95%CI = 1.14-2.37, p = 0.008) in estrogen receptor (ER) negative patients. CONCLUSION: The PRS could provide additional information for Chinese women at high risk of breast cancer and holds significant value for BC screening. An increase in PRS also indicates an unfavorable prognosis and might play a crucial role in the clinical management of breast cancer patients at the time of diagnosis.

doi.org/10.1186/s40246-026-01021-xOpen accessPubMed 43015903Biomarkers

AgingResearch.News